Breaking News

Transgenomic, Raptor Enter Genetic Testing Services Pact

April 4, 2014

Will provide testing services for Raptor’s trial in Leigh syndrome

Transgenomic, Inc. has entered an agreement with Raptor Pharmaceuticals, Inc. to provide genetic testing services for Raptor’s clinical trial evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders. Leigh syndrome is a severe neurological disorder characterized by progressive loss of mental and movement abilities and typically results in death within a few years, usually due to respiratory failure.
 
“We look forward to working with Raptor and the study investigators, using our leading-edge mitochondrial genetic testing capabilities to uncover the important genetic profiling information required for the successful execution of this clinical trial,” said Paul Kinnon, president and chief executive officer of Transgenomic. “This is a key example of how Transgenomic works with pharmaceutical companies to employ complementary genetic tests designed to improve clinical diagnoses and outcomes.”
  • Biopharma Fill Finish Contract Manufacturing Market

    Biopharma Fill Finish Contract Manufacturing Market

    Cindy Liu and William Downey, HighTech Business Decisions||November 9, 2016
    Outsourcing strategies and areas of market opportunities

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research